Comments
Drug firm Suven Life Sciences today announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of a major depressive disorder.
In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a “novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing... and the topline results from the study is expected during the quarter January-March 2018".
Suven Life CEO Venkat Jasti said: “Progression of SUVN-911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD).”
Suven Life said the global antidepressant market is valued over $20 billion.
Suven Life Sciences shares were trading 1.01 per cent up at Rs 75.80 on BSE in morning trade.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.